{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:31:36Z","timestamp":1767652296549},"reference-count":26,"publisher":"Cambridge University Press (CUP)","issue":"2","license":[{"start":{"date-parts":[[2015,4,17]],"date-time":"2015-04-17T00:00:00Z","timestamp":1429228800000},"content-version":"unspecified","delay-in-days":16,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Disaster med. public health prep."],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec id=\"S1935789314001566_abs1\" sec-type=\"general\"><jats:title>Objective<\/jats:title><jats:p>The Centers for Disease Control and Prevention estimated that up to 88 million H1N1 influenza cases, 398,000 hospitalizations, and up to 18,050 related deaths, including significant racial and ethnic disparities, occurred between April 2009 and March 13, 2010. The Food and Drug Administration (FDA) approved emergency use authorizations (EUAs), which allowed the distribution of unapproved drugs or the off-label use of approved drugs. In late 2009, peramivir was granted an EUA for patients with severe disease. This study examined factors associated with willingness to take peramivir.<\/jats:p><\/jats:sec><jats:sec id=\"S1935789314001566_abs2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>In 2010 we conducted a nationally representative survey with 2079 respondents randomly drawn from the Knowledge Networks research panel. Our completion rate was 56%. Respondents received information about peramivir from a fact sheet and then answered questions about their willingness to take the drug.<\/jats:p><\/jats:sec><jats:sec id=\"S1935789314001566_abs3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>Overall, 48% of participants indicated that they would probably or definitely take peramivir. Seventy-nine percent definitely would take the drug if their doctor recommended it and there were no alternative treatments. There were significant racial differences in willingness. The term<jats:italic>experimental<\/jats:italic>to refer to the drug decreased willingness to accept peramivir among both whites and blacks.<\/jats:p><\/jats:sec><jats:sec id=\"S1935789314001566_abs4\" sec-type=\"conclusions\"><jats:title>Conclusions<\/jats:title><jats:p>Trust in the FDA was important for peramivir acceptance. Particular care must be taken to ensure that patients and their families understand the complex nature of EUA drugs. Lessons learned can inform communication about future EUAs. (<jats:italic>Disaster Med Public Health Preparedness<\/jats:italic>. 2015;9:166-174)<\/jats:p><\/jats:sec>","DOI":"10.1017\/dmp.2014.156","type":"journal-article","created":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T23:07:48Z","timestamp":1435792068000},"page":"166-174","source":"Crossref","is-referenced-by-count":13,"title":["Public Acceptance of Peramivir During the 2009 H1N1 Influenza Pandemic: Implications for Other Drugs or Vaccines Under Emergency Use Authorizations"],"prefix":"10.1017","volume":"9","author":[{"given":"Sandra Crouse","family":"Quinn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Hilyard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nestor","family":"Castaneda-Angarita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicki S.","family":"Freimuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2015,4,17]]},"reference":[{"key":"S1935789314001566_ref19","unstructured":"Advancing Regulatory Science at FDA: A Strategic Plan. US Food and Drug Administration website. 2011. http:\/\/www.fda.gov\/downloads\/scienceresearch\/specialtopics\/regulatoryscience\/ucm268225.pdf. Accessed November 29, 2012."},{"key":"S1935789314001566_ref4","first-page":"913","article-title":"Pandemic Influenza A (H1N1) Virus Infections-Chicago, Illinois, April-July 2009","volume":"58","year":"2009","journal-title":"Morbid Mortal Wkly Rep"},{"key":"S1935789314001566_ref15","unstructured":"FDA-issued Peramivir EUA letter. Centers for Disease Control and Prevention website. http:\/\/www.cdc.gov\/h1n1flu\/eua\/EUA%20Peramivir%20Letter%20-%20Frieden.pdf. Accessed May 28, 2013."},{"key":"S1935789314001566_ref1","unstructured":"CDC Estimates of 2009 H1N1 Influenza Cases, Hospitalizations and Deaths in the United States, April 2009-March 13, 2010. Centers for Disease Control and Prevention website. http:\/\/www.cdc.gov\/h1n1flu\/estimates\/April_March_13.htm. Accessed May 28, 2013."},{"key":"S1935789314001566_ref23","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2013.301706"},{"key":"S1935789314001566_ref10","unstructured":"Guidance Emergency Use Authorization of Medical Products. US Food and Drug Administration (FDA) website. 2007. http:\/\/www.fda.gov\/RegulatoryInformation\/Guidances\/ucm125127.htm. Accessed May 28, 2013."},{"key":"S1935789314001566_ref20","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2009.162537"},{"key":"S1935789314001566_ref24","unstructured":"Questions and Answers for Hospitals and Healthcare Professionals Regarding Termination of the Emergency Use Authorization for Peramivir IV. US Food and Drug Administration website. June 22, 2010. http:\/\/www.cdc.gov\/H1N1flu\/EUA\/pdf\/Peramivir_Attachment_22Jun2010.pdf. Accessed May 28, 2013."},{"key":"S1935789314001566_ref17","unstructured":"Centers for Disease Control and Prevention. Influenza vaccination coverage-United States, 2000-2010. Morb Mortal Wkly Rep. 2011;60:38-41."},{"key":"S1935789314001566_ref8","unstructured":"Interim Questions and Answers about Emergency Use Authorization. Centers for Disease Control and Prevention website. http:\/\/www.cdc.gov\/h1n1flu\/eua\/. Accessed June 4, 2010."},{"key":"S1935789314001566_ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906695"},{"key":"S1935789314001566_ref13","unstructured":"Termination of the Emergency Use Authorization (EUA) of Medical Products and Devices. Centers for Disease Control and Prevention website. http:\/\/www.cdc.gov\/h1n1flu\/eua\/. Accessed May 28, 2013."},{"key":"S1935789314001566_ref11","doi-asserted-by":"publisher","DOI":"10.3201\/eid1307.061188"},{"key":"#cr-split#-S1935789314001566_ref21.1","unstructured":"9. Plain Writing Act of 2010. Government Printing Office"},{"key":"#cr-split#-S1935789314001566_ref21.2","unstructured":"10. (GPO) website. http:\/\/www.plainlanguage.gov\/plLaw\/. Accessed December 16, 2013."},{"key":"S1935789314001566_ref12","doi-asserted-by":"publisher","DOI":"10.1089\/bsp.2009.0603"},{"key":"S1935789314001566_ref14","unstructured":"Emergency use authorization of Peramivir fact sheet for patients and parents\/caregivers. US Food and Drug Administration (FDA) website. http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/UCM187799.pdf. Accessed May 28, 2013."},{"key":"S1935789314001566_ref9","doi-asserted-by":"publisher","DOI":"10.1089\/bsp.2009.0041"},{"key":"S1935789314001566_ref18","doi-asserted-by":"publisher","DOI":"10.1089\/bsp.2012.0048"},{"key":"#cr-split#-S1935789314001566_ref6.1","doi-asserted-by":"crossref","unstructured":"12. Loganathan R, Sitnitskaya Y, Schori M, et al. Urban Inner-City Minority New Yorkers Hospitalized with Novel Swine-Origin Influenza A H1N1 Virus Illness During the Pandemic of April-June 2009. Internet J Emerg Intensive Care Med. 2010;12","DOI":"10.5580\/fe1"},{"key":"#cr-split#-S1935789314001566_ref6.2","unstructured":"13. . http:\/\/ispub.com\/IJEICM\/12\/1\/7091. Accessed March 2, 2011."},{"key":"S1935789314001566_ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0910479"},{"key":"S1935789314001566_ref3","doi-asserted-by":"publisher","DOI":"10.1097\/DMP.0b013e3181c6b818"},{"key":"S1935789314001566_ref5","first-page":"201","article-title":"Epidemiologic and clinical features among patients hospitalized in Wisconsin with 2009 H1N1 influenza A virus infections, April to August 2009","volume":"109","author":"Chitnis","year":"2010","journal-title":"WMJ"},{"key":"S1935789314001566_ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0277-9536(00)00178-7"},{"key":"S1935789314001566_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2011.03.002"}],"container-title":["Disaster Medicine and Public Health Preparedness"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1935789314001566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T18:33:40Z","timestamp":1566930820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1935789314001566\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S1935789314001566"],"URL":"https:\/\/doi.org\/10.1017\/dmp.2014.156","relation":{},"ISSN":["1935-7893","1938-744X"],"issn-type":[{"value":"1935-7893","type":"print"},{"value":"1938-744X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4]]}}}